Gadolinium MRI Contrast Dye Manufacturers
Gadolinium-based contrast agents (GBCAs) are produced by 4 different pharmaceutical companies in the United States.
1. Bracco
History: Founded in 1927 by Milan Elio Bracco in Italy. Began international expansion in 1987. Entered the U.S. market in 1994 with the creation of Bracco Diagnostics, Inc. and Bracco Research USA.
| Headquarters: |
Princeton, New Jersey (Bracco Diagnostics, Inc.) |
|
Italy (Bracco) |
Locations: Present in over 115 countries with major entities in Italy, Switzerland, Germany, England, Netherlands, Austria, United States, Canada, China, Singapore, and Japan.
Employees: ~ 2,100 employees worldwide
Net Sales: 769 million Euros in 2005 (more than $1 billion U.S. dollars)
GBCA Products: MultiHance and ProHance
Bracco Diagnostics Inc. is responsible for developing new clinical agents, filing them with the FDA, and selling all Bracco products within the United States and Canada.
2. GE Healthcare
Headquarters: Chalfont St. Giles, United Kingdom
Employees: More than 46,000 people worldwide
Locations: In more than 100 countries
Net worth: $17 billion dollars
| Revenues: |
$16.6 billion dollars in 2006 |
|
$15.2 billion dollars in 2005 |
|
$6 billion dollars in 2000 |
GBCA Product: Omniscan
GE Healthcare is a unit of General Electric Company.
3. Bayer Healthcare
Headquarters: Leverkusen, Germany
Employees: More than 50,000 people worldwide
Sales: 11,724 million Euros in 2006 = (~$16 billion U.S. dollars)
GBCA Product: Magnevist
Magnevist was Bayer Healthcare's 9th best-selling product in 2006 with sales totaling 323 million Euros (over $440 million U.S. dollars).
4. Mallinckrodt, Inc.
History: Founded by brothers Edward, Otto, and Gustav Mallinckrodt in 1867. Bought by Tyco International and became a business unit of Tyco Healthcare in 2000. On June 29, 2007, Tyco Healthcare split into 3 separate publicly-traded companies, with Mallinckrodt operating within Covidien, a stand-alone healthcare company. Covidien began trading as a public company on July 2, 2007.
| Headquarters: |
Hazelwood, Missouri (Mallinckrodt) |
|
Mansfield, Massachusetts (Covidien) |
| Locations: |
14 in the United States, 2 in Canada, 1 in United Kingdom (Mallinckrodt) |
|
65 manufacturing facilities in 16 countries (Covidien) |
|
Covidien sales representatives in more than 50 countries |
|
Covidien products distributed in over 130 countries |
| Employees: |
Mallinckrodt employs more than 12,000 people worldwide |
|
Covidien employs more than 43,000 people worldwide |
Revenue: $9.6 billion dollars in 2006 (Covidien)
GBCA Product: OptiMARK
Covidien is the ninth largest pharmaceutical company in the U.S., based on the number of prescriptions dispensed.
